Celtaxsys

/files/logo_portfolio/200x200_resize_CTXBMP.png
Site
Stage of funding:Current
Therapeutic group:Inflammatory Diseases
Type:Drug

Description

Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. The company is building a sustainable pipeline of first-in-class immuno-modulators.

The lead drug candidate, acebilustat is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in the production of the powerful promoter of inflammation Leukotriene B4 (LTB4). Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). Acebilustat has been shown to be effective in several CF-related, pre-clinical and clinical models and has been well tolerated in healthy volunteers and CF patients. 

Celtaxsys is located in Atlanta, GA with a subsidiary office in Brisbane, Queensland, Australia.

Return

Leadership

Portfolio companies news